DNA Electronics

As a longer-term product, the firm is developing a sequencing test for the clinic that could enable identifying a broad range of sepsis pathogens and detecting antimicrobial resistance.

Under the contract, DNAe will develop tests for antimicrobial resistant infections and influenza that it submits to the FDA for clearance. 

The test is based on a biomarker signature that consists of a core set of 31 genes associated with endotoxin tolerance in sepsis patients.

The company is also developing a next-generation sequencing product that may be applied at the point of need to test for bloodstream infections and later as a liquid biopsy for cancer.

The London-based firm plans to fund development and clinical trials for its point-of-care diagnostic test for serious blood infections.

DNAe will combine its semiconductor DNA sequencing technology with nanoMR's PCS technology for a complete blood-to-result solution.

NEW YORK (GenomeWeb) – London-based DNA Electronics is developing a point-of-care diagnostic platform that can amplify, genotype via real-time PCR, and do targeted semiconductor sequencing all on one chip.

Cepheid said this week that it has appointed Peter Farrell as executive vice president of international commercial operations.

Qiagen said this week that Detlev Riesner, a Qiagen co-founder, retired earlier this month as chairman of the company's supervisory board after having served as a member of the board since 1996 and as chairman since 2003.

Pages

A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.

Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.